Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Trial Profile

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pramlintide (Primary)
  • Indications Hypoglycaemia
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 04 Apr 2019 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified April 2017).
    • 31 Aug 2018 Biomarkers information updated
    • 25 Apr 2017 Planned End Date changed from 1 May 2015 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top